AMONDYS 45 casimersen Updated Nov 8
Watch for the FDA's decision on the sNDA for traditional approval of AMONDYS 45, expected around April 2027 (standard review timeline from the June 30, 2026 acceptance). Approval would remove the overhang from the failed ESSENCE confirmatory trial and solidify the PMO franchise's revenue stream. Denial could threaten the drug's continued marketing and would be a significant negative for SRPT shares.
- AMONDYS 45 is already approved under accelerated approval (February 2021) and is generating significant revenue as part of Sarepta's PMO franchise, which delivered $240.3M in Q3 2026 net product revenue and drove the company to raise full-year guidance.
- The FDA accepted the sNDA for traditional approval despite the ESSENCE trial miss, suggesting regulators see a path forward. Sarepta's management has expressed confidence that there is no risk of losing marketing authorization.
- The drug addresses a clear unmet need for Duchenne muscular dystrophy patients with exon 45 skipping-amenable mutations, a defined genetic subset with few treatment options.
- The Phase 3 ESSENCE confirmatory trial failed to meet its primary endpoint in November 2025, raising fundamental questions about the drug's efficacy. The FDA accepted the sNDA for review despite this failure, but the odds of conversion to traditional approval are uncertain.
- If the FDA denies the sNDA, the drug's accelerated approval could face withdrawal proceedings, threatening a major portion of Sarepta's revenue stream (the PMO franchise generated $240.3M in Q3 2026).
- Sarepta faces competitive pressure from Dyne Therapeutics' z-rostudirsen (targeting exon 51), which has a PDUFA date of January 21, 2027 under priority review, potentially eroding the franchise.